Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137.

View in: PubMed

subject areas

Animals
Antigens, Neoplasm
Clinical Trials as Topic
Genetic Engineering
Hematologic Neoplasms
Humans
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell
T-Lymphocytes
Treatment Outcome

authors with profiles

Michael Bishop